interleukin 6

A chessboard with blocks that read MA
Biotech

Novartis spends $1.4B for Tourmaline, CV med that wowed in ph. 2

Novartis is paying $1.4 billion to get its hands on Tourmaline and its former Pfizer cardiovascular drug that impressed in a phase 2 study this year.
James Waldron Sep 9, 2025 4:28am
IBD

I-Mab's IL-6 drug hits goal in ulcerative colitis phase 2

Apr 26, 2021 8:45am
Lung Fibrosis

Lassen Therapeutics, Cedars Sinai team up on lung fibrosis work

Mar 25, 2021 9:20am
Roche

Roche test OK’d to identify high-risk COVID-19 patients

Jun 4, 2020 10:50am